Press releases

Acceleration of the Antibiotics program: €14.6m of funding by Bpifrance (including € 10.4m for the DEINOVE Group) and structuring of the...

The program developed by REDX PHARMA focuses on a new class of antibiotics aimed at treating the most lethal infections (caused by...

DEINOVE expands the AGIR project’s field of investigation for the discovery of novel antibiotic structures by accessing the strain bank of...

World premiere in Deinococcus fermentation successfully performed at the several cubic meters scale; The first batch of carotenoid...

DEINOVE (Euronext Growth Paris: ALDEI), a biotech company that discovers, develops, and produces high-value compounds from rare bacteria,...

Development of an innovative cosmetic active ingredient combining the exclusive properties of Deinove’s strains and Oléos' patented Oleo-...

Deinove’s production process gaining momentum: fermentation scale-up is planned at the BIOGIS Center, SAS PIVERT's technological platform...

Six pre-selected strains are in the testing phase to validate the final choice of the active ingredient to be marketed in 2018. Technology...

This active ingredient with proven antioxidant and healing properties is an innovative carotenoid produced by Deinococcus bacteria. The...

Cash position: +€6.6m at June 30, 2017 compared to +€9.3m at December 31, 2016. Half-year net loss of DEINOVE Group (composed of DEINOVE...